Home › Cardiomyopathy › Oregon
Cardiomyopathy clinical trials in Oregon
3 studies for Cardiomyopathy are looking for participants at sites in Oregon.
Cities in Oregon
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Oregon Health and Science University (OHSU), Portland
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Nov 4, 2026 · NCT06128629TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, Portland
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Oct 20, 2026 · NCT07052903Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Oregon Health & Science University, Portland
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.